Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Karuna Therapeutics, Inc.
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
February 22, 2024
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
December 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
BMY
KRTX
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
December 14, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
November 29, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
November 16, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
November 01, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
November 01, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
October 19, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
October 04, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
September 28, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
August 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Leadership Appointments
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
July 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
May 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
May 04, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
April 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
March 24, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
March 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
March 21, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
February 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
February 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
January 31, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
December 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Tickers
KRTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
